Drugs, Dosages, Forms Approved Overseas but not Available in the USA? (Reciprocity)

[removed]

Posted Dec 14, 2020, 3:51 PM UTC

15
RevolutionaryMoney•

I'm not a doctor, but developed a layman's interest in addiction medicine due to a loved one. There is a drug Ibudilast that is used in Japan mostly as a treatment for Asthma and is not FDA approved. It seems to have potential to help with several neurological and psychiatric conditions (e.g., AUD ) and there are several FDA studies underway by MediciNova (I believe they had postive Phase II results for AUD in the summer).

I'm not qualified to asses it, but effective medications for addiction are few and far between so I find it interesting.

4
SkipperdogsRN RPh•

We (US addiction and recovery) had an EM physician check into treatment for tianeptine addiction. (Available in Europe with a prescription.)

Tianeptine, sold under the brand names Stablon and Coaxil among others, is an atypical antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.[1][2][3]

It was a difficult withdrawal for him with acute symptoms lasting 7 days. I was totally unfamiliar with it.

Tianeptine has antidepressant and anxiolytic effects[9] with a relative lack of sedative, anticholinergic, and cardiovascular side effects.[7][10] It has been found to act as an atypical agonist of the μ-opioid receptor with clinically negligible effects on the δ- and κ-opioid receptors as do most tricyclic antidepressants (TCA).[11][12][13]

He was able to complete our program successfully and return to practice.

3
JackTheRascalOPMD•

I'll start- an Optometrist told me the following: "I once visited Alcon's facility in Fort Worth. They had a display in their lobby of all their drugs under a glass case. One of them was "DuoTrav" which is a combination of travoprost and timolol which is not available in the US. I thought this was kind of an odd combo, as you generally dose prostaglandin analogs like travoprost before bedtime, but you don't do the same with timolol (it does not work well when the patient is asleep)"

2
chi_lawyerJD•

The article doesn't address the entire picture to this non-physician. You also have older drugs for which there is insufficient incentive for someone to go through the work of getting the drug approved here and/or getting new dosage forms or methods of administration approved.

To deal with that problem, I'd suggest some sort of minimal-review reciprocity for a drug that has been on the market in multiple developed countries for an extended period of time, OR (where the drug is approved in the US AND a dosage / method of administration is approved in several developed countries), OR the new dose is lower than the highest dosage form and is pretty obviously OK (e.g., smaller doses of benzos to aid in slow tapering, vs. having to have them compounded).

2
JackTheRascalOPMD•

Thanks, non-physician! (I’m a lawyer too). I’m a lawyer too. The article is only tangentially related to the rest of the post, which is not meant to suggest policy changes. It’s not even meant to be a regulatory or legislative backdrop- just an article that made me wonder which drugs/combos have not made it to the US.

1
[deleted]•

[deleted]

1